HEREDITARY HEMORRHAGIC TELANGIECTASIA
Clinical trials for HEREDITARY HEMORRHAGIC TELANGIECTASIA explained in plain language.
Never miss a new study
Get alerted when new HEREDITARY HEMORRHAGIC TELANGIECTASIA trials appear
Sign up with your email to follow new studies for HEREDITARY HEMORRHAGIC TELANGIECTASIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Can a cancer drug stop chronic nosebleeds? new trial for HHT patients
Disease control OngoingThis study tests whether bevacizumab, a drug that blocks a protein involved in abnormal blood vessel growth, can reduce chronic bleeding and iron-deficiency anemia in people with hereditary hemorrhagic telangiectasia (HHT). HHT causes fragile blood vessels that bleed easily, ofte…
Matched conditions: HEREDITARY HEMORRHAGIC TELANGIECTASIA
Phase: PHASE2 • Sponsor: Hanny Al-Samkari, MD • Aim: Disease control
Last updated May 26, 2026 04:37 UTC
-
Could a daily pill stop debilitating nosebleeds for HHT patients?
Symptom relief OngoingThis study tests whether a low dose of the drug pazopanib, taken daily for 24 weeks, can reduce the severity and duration of nosebleeds in people with hereditary hemorrhagic telangiectasia (HHT), a condition that causes frequent bleeding. About 70 participants will receive either…
Matched conditions: HEREDITARY HEMORRHAGIC TELANGIECTASIA
Phase: PHASE2, PHASE3 • Sponsor: Cure HHT • Aim: Symptom relief
Last updated May 26, 2026 05:14 UTC
-
HHT patients wanted for landmark registry study
Knowledge-focused OngoingThis study is creating a registry of up to 1,000 adults with Hereditary Hemorrhagic Telangiectasia (HHT) from four North American centers. Researchers will collect health information over time to learn how the disease changes and what factors affect those changes. The goal is to …
Matched conditions: HEREDITARY HEMORRHAGIC TELANGIECTASIA
Sponsor: Unity Health Toronto • Aim: Knowledge-focused
Last updated May 18, 2026 12:11 UTC